Zobrazeno 1 - 10
of 19
pro vyhledávání: ''
Autor:
Filippo de Marinis, Francesca Porta, Elena Guerini-Rocco, Carmine Valenza, Giuseppe Curigliano, Chiara Catania, Alessandra Rappa, Massimo Barberis, Giuseppe Viale
Publikováno v:
Current Oncology, Vol 28, Iss 292, Pp 3384-3392 (2021)
Current Oncology
Current Oncology
We present a case of a woman with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma who received gefitinib for 2 years and obtained a partial response. The patient then developed liver metastasis and a breast lesion, displaying high
Publikováno v:
Current Oncology, Vol 28, Iss 168, Pp 1803-1822 (2021)
Current Oncology
Current Oncology
Background: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is the most prevalent breast cancer. Endocrine therapy is the mainstay of treatment, however, due to the heterogeneous nature of the disease, resistance to endocrine ther
Publikováno v:
Current Oncology, Vol 28, Iss 66, Pp 678-688 (2021)
Current Oncology
Volume 28
Issue 1
Pages 66-688
Current Oncology
Volume 28
Issue 1
Pages 66-688
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative
Autor:
Mark Clemons, Rachel Anne Goodwin, A Imbulgoda, Tharshika Thangarasa, Patricia A. Tang, Joanna Gotfrit, Michael M. Vickers
Publikováno v:
Current Oncology. 26:162-166
Background The optimal management of hypomagnesemia (hMg) induced by epidermal growth factor receptor inhibitors (egfris) for advanced colorectal cancer is unclear. We surveyed gastrointestinal medical oncologists in Canada to determine practice patt
Autor:
Vera Hirsh, S. Morin–Ben Abdallah
Publikováno v:
Current Oncology. 25:9-17
Despite recent advances in the systemic therapy of non-small-cell lung cancer (NSCLC), the prognosis for stage IV disease remains poor. The discovery of targetable mutations has led to new treatment options. The most common mutations, the EGFR activa
Autor:
A Azad, K. Hui, Ellen Warner, S Ahmed, S Sridhar, D C Hodgson, K Morarji, O McArdle, Ellen M. Greenblatt, A M F Ali, G Gingras-Hill
Publikováno v:
Current Oncology
Volume 24
Issue 6
Pages 3335-502
Volume 24
Issue 6
Pages 3335-502
As cure rates for breast cancer improve, there is increasing evidence that late effects of treatment&mdash
and impaired fertility in particular&mdash
are emerging as important concerns among young breast cancer survivors. Older reports have
and impaired fertility in particular&mdash
are emerging as important concerns among young breast cancer survivors. Older reports have
Publikováno v:
Current Oncology
Volume 22
Issue 5
Pages 2635-399
Volume 22
Issue 5
Pages 2635-399
Kaposi sarcoma (ks) is a vascular tumour caused by oncogenic human herpesvirus type 8
it often occurs with hiv-associated immunosuppression. Numerous cellular signalling pathways are involved in the pathogenesis of ks, among which receptor tyros
it often occurs with hiv-associated immunosuppression. Numerous cellular signalling pathways are involved in the pathogenesis of ks, among which receptor tyros
Publikováno v:
Current Oncology
Volume 22
Issue 3
Pages 2566-215
Volume 22
Issue 3
Pages 2566-215
This systematic review addresses the use of epidermal growth factor receptor (egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients&mdash
unselected, selected, and molecularly selected&mdash
in three
unselected, selected, and molecularly selected&mdash
in three
Publikováno v:
Current Oncology
Volume 19
Issue 5
Pages 1011-268
Volume 19
Issue 5
Pages 1011-268
Most women with advanced breast cancer will develop bone metastases, which are associated with the development of skeletal-related events (sres) such as pathologic fractures and spinal cord compression. This article reviews the evolving definition an
Publikováno v:
Current Oncology
Volume 19
Issue 11
Pages 1149-44
Volume 19
Issue 11
Pages 1149-44
New drugs such as pemetrexed, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, and the Alk inhibitor crizotinib have recently enabled progress in the management of advanced non-small-cell lung cancer (NSCLC). More drugs, especi